Effects of phlebotomy therapy on cytochrome P450 2e1 activity and oxidative stress markers in dysmetabolic iron overload syndrome: A randomized trial

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 8, 2006, Pages 1207-1213

  Laine F ^a   Reymann, J M ^a   Morel, F ^b   Langouet S ^b   Perrin, M ^a   Guillygomarc'h, A ^a   Brissot, P ^a   Turmel, V ^a   Mouchel, C ^a   Pape, D ^a   Bellissant, E ^a   Deugnier, Y ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYCHLORZOXAZONE; ALPHA TOCOPHEROL; ASCORBIC ACID; BIOLOGICAL MARKER; CHLORZOXAZONE; CYTOCHROME P450 2E1; FERRITIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HUMAN; IRON OVERLOAD; IRON STORAGE; OXIDATIVE STRESS; PHLEBOTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION; TREATMENT OUTCOME;

ASCORBIC ACID; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CYTOCHROME P-450 CYP2E1; FERRITINS; HUMANS; IRON OVERLOAD; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PHLEBOTOMY; PROSPECTIVE STUDIES; VITAMIN E;

EID: 33748918135     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03116.x     Document Type: Article

References (24)

1. Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997; 349: 95-7.
2. Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155-63.
3. Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc'h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol 2001; 116: 263-70.
4. Guillygomarc'h A, Mendler MH, Moirand R, et al. Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol 2001; 35: 344-9.
5. Roblin X, Phelip JM, Hilleret MN, Heluwaert F, Bonaz B, Zarski JP. Correction of insulin resistance syndrome does not cause normalisation of hyperferritinaemia. Gastroenterol Clin Biol 2003; 27: 1079-83.
6. Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004; 363: 357-62.
7. Barry M, Sherlock S. Measurement of liver-iron concentration in needle-biopsy specimens. Lancet 1971; 1: 100-3.
8. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
9. Lucas D, Ferrara R, Gonzalez E, et al. Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. Pharmacogenetics 1999; 9: 377-88.
10. Lucas D, Berthou F, Girre C, Poitrenaud F, Menez JF. High-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in serum: a tool for indirect evaluation of cytochrome P4502E1 activity in humans. J Chromatogr 1993; 622: 79-86.
11. Speek AJ, Schrijver J, Schreurs WH. Fluorometric determination of total vitamin C in whole blood by high-performance liquid chromatography with pre-column derivatization. J Chromatogr 1984; 305: 53-60.
12. De Leenheer AP, De Bevere VO, Cruyl AA, Claeys AE. Determination of serum alpha-tocopherol (vitamin E) by high-performance liquid chromatography. Clin Chem 1978; 24: 585-90.
13. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997; 77: 517-44.
14. Cederbaum AI. Iron and CYP2E1-dependent oxidative stress and toxicity. Alcohol 2003; 30: 115-20.
15. Stal P, Johansson I, Ingelman-Sundberg M, Hagen K, Hultcrantz R. Hepatotoxicity induced by iron overload and alcohol. Studies on the role of chelatable iron, cytochrome P450 2E1 and lipid peroxidation. J Hepatol 1996; 25: 538-46.
16. Chalasani N, Gorski JC, Asghar MS, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003; 37: 544-50.
17. Emery MG, Fisher JM, Chien JY, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003; 38: 428-35.
18. Brissot P, Deugnier Y, Le Treut A, Regnouard F, Simon M, Bourel M. Ascorbic acid status in idiopathic hemochromatosis. Digestion 1978; 17: 479-87.
19. Kom GD, Schwedhelm E, Nielsen P, Boger RH. Increased urinary excretion of 8-iso-prostaglandin F2alpha in patients with HFE-related hemochromatosis: a case-control study. Free Radic Biol Med 2006; 40: 1194-200.
20. Facchini FS, Saylor KL. Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients. Ann N Y Acad Sci 2002; 967: 342-51.
21. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 931-9.
22. Fargion S, Dongiovanni P, Guzzo A, Colombo S, Valenti L, Fracanzani AL. Iron and insulin resistance. Aliment Pharmacol Ther 2005; 22: 61-3.
23. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002; 51: 1000-4.
24. Piperno A, Vergani A, Salvioni A, et al. Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. Liver Int 2004; 24: 471-6.